Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Circulating tumor cells as a predictor for poor prognostic factors and overall survival in treatment naïve oral squamous cell carcinoma patients.
Qayyumi B, Bharde A, Aland G, D'Souza A, Jayant S, Singh N, Tripathi S, Badave R, Kale N, Singh B, Arora S, Gore I, Singh A, Vasudevan A, Prabhash K, Khandare J, Chaturvedi P. Qayyumi B, et al. Among authors: gore i. Oral Surg Oral Med Oral Pathol Oral Radiol. 2022 Jul;134(1):73-83. doi: 10.1016/j.oooo.2022.02.018. Epub 2022 Mar 6. Oral Surg Oral Med Oral Pathol Oral Radiol. 2022. PMID: 35595620
Developmental mosaicism underlying EGFR-mutant lung cancer presenting with multiple primary tumors.
Burr R, Leshchiner I, Costantino CL, Blohmer M, Sundaresan T, Cha J, Seeger K, Guay S, Danysh BP, Gore I, Jacobs RA, Slowik K, Utro F, Rhrissorrakrai K, Levovitz C, Barth JL, Dubash T, Chirn B, Parida L, Sequist LV, Lennerz JK, Mino-Kenudson M, Maheswaran S, Naxerova K, Getz G, Haber DA. Burr R, et al. Among authors: gore i. Nat Cancer. 2024 Nov;5(11):1681-1696. doi: 10.1038/s43018-024-00840-y. Epub 2024 Oct 15. Nat Cancer. 2024. PMID: 39406916 Free PMC article.
Germline mutations and developmental mosaicism underlying EGFR-mutant lung cancer.
Burr R, Leshchiner I, Costantino CL, Blohmer M, Sundaresan T, Cha J, Seeger K, Guay S, Danysh BP, Gore I, Jacobs RA, Slowik K, Utro F, Rhrissorrakrai K, Levovitz C, Barth JL, Dubash T, Chirn B, Parida L, Sequist LV, Lennerz JK, Mino-Kenudson M, Maheswaran S, Naxerova K, Getz G, Haber DA. Burr R, et al. Among authors: gore i. medRxiv [Preprint]. 2023 Sep 29:2023.09.28.23296274. doi: 10.1101/2023.09.28.23296274. medRxiv. 2023. Update in: Nat Cancer. 2024 Nov;5(11):1681-1696. doi: 10.1038/s43018-024-00840-y PMID: 37808694 Free PMC article. Updated. Preprint.
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.
Holmes FA, Moy B, Delaloge S, Chia SKL, Ejlertsen B, Mansi J, Iwata H, Gnant M, Buyse M, Barrios CH, Silovski T, Šeparović R, Bashford A, Zotano AG, Denduluri N, Patt D, Gokmen E, Gore I, Smith JW 2nd, Loibl S, Masuda N, Tomašević Z, Petráková K, DiPrimeo D, Wong A, Martin M, Chan A; ExteNET Study Group. Holmes FA, et al. Among authors: gore i. Eur J Cancer. 2023 May;184:48-59. doi: 10.1016/j.ejca.2023.02.002. Epub 2023 Feb 10. Eur J Cancer. 2023. PMID: 36898233 Free article. Clinical Trial.
133 results